A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective.
Carcinoid syndrome
Hemodialysis
Portal systemic encephalopathy
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
21
10
2022
accepted:
31
07
2023
medline:
22
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
aheadofprint
Résumé
Carcinoid syndrome is caused by the release of serotonin and other substances, which commonly occurs due to liver metastasis of neuroendocrine tumors. It rarely occurs due to liver metastasis of neuroendocrine carcinoma. We report the case of a patient with liver metastasis of neuroendocrine carcinoma who suffered from acute abdominal pain and diarrhea triggered by hemodialysis. Various differential diagnoses were considered, but we concluded these symptoms to be probably caused by exacerbation of carcinoid syndrome, as the serum 5HIAA level was markedly elevated, and a drug with anti-serotonin activity was effective. Prochlorperazine maleate, which has anti-serotonin activity, was effective for these symptoms, and the patient was able to continue maintenance hemodialysis, which contributed to his quality of life and prognosis. We speculated the mechanism of carcinoid exacerbation was that substances such as serotonin had entered the systemic circulation via the increased extrahepatic shunt of the portal venous blood flow, entering the inferior vena cava and that this condition had been triggered by hemodialysis via the same mechanism as portal systemic encephalopathy.
Identifiants
pubmed: 37606883
doi: 10.1007/s13730-023-00814-6
pii: 10.1007/s13730-023-00814-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Japanese Society of Nephrology.
Références
https://docs.jsdt.or.jp/overview/file/2020/pdf/06.pdf . Accessed 28 July 2023
Liu EH, Solorzano CC, Katznelson L, et al. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.
doi: 10.4158/EP14464.DSC
pubmed: 25962092
pmcid: 4987303
Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–34.
doi: 10.1016/S1470-2045(17)30110-9
pubmed: 28238592
pmcid: 6066284
Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3–7.
doi: 10.1159/000080731
pubmed: 15477707
Ubara Y, Hoshino J, Tagami T, et al. Hemodialysis-related portal-systemic encephalopathy. Am J Kidney Dis. 2004;44:e38–42.
doi: 10.1016/S0272-6386(04)00826-1
pubmed: 15332238
Klimstra D, Klöppel G, La Rosa S, et al. Classification of neuroendocrine neoplasm of the digestive system. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumours, digestive system tumours. 5th edn, vol. 1. Lyon: World Health Organization; 2019. p. 16–21.
Georgiadou F, Moutzouris DA, Kassimatis TI, et al. Recurrent flushing in a hemodialysis patient. Semin Dial. 2006;19:558–9.
doi: 10.1111/j.1525-139X.2006.00222.x
pubmed: 17150061
Irvin MM, Mard K, Igor L, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.
doi: 10.1053/j.gastro.2005.03.038
Fandulli G, Ruggeri RM, Glossrubatscher E, et al. Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord. 2020;21:599–612.
doi: 10.1007/s11154-020-09547-8
Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2015;52:554–60.
Sebekova K, Spustova V, Opatrny K Jr, et al. Serotonin and 5-hydroxyindole-acetic acid. Bratisl Lek Listy. 2001;102:351–6.
pubmed: 11763663
Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med. 1986;315:663–6.
doi: 10.1056/NEJM198609113151102
pubmed: 2427948
Vitale G, Carra S, Alessi Y, et al. Carcinoid syndrome preclinical models and future therapeutic strategies. Int J Mol Sci. 2023;24:3610.
doi: 10.3390/ijms24043610
pubmed: 36835022
pmcid: 9961914